雄激素受体表达情况与人表皮生长因子受体2过表达型及三阴性乳腺癌患者新辅助化疗敏感性的关系  

Relationship between androgen receptor expression and sensitivity of human epidermal growth factor receptor 2 overexpression and triple negative breast cancer patients to neoadjuvant chemotherapy

作　　者：孙宇[1] 黎冠宏[1] 王存富 董菊红[1] 邓素华[1] SUN Yu;LI Guanhong;WANG Cunfu;DONG Juhong;DENG Suhua(Breast Center,the Third People's Hospital of Huizhou City,Guangdong Province,Huizhou 516002,China)

机构地区：[1]广东省惠州市第三人民医院乳腺中心,广东惠州516002

出　　处：《中国当代医药》2023年第8期100-103,共4页China Modern Medicine

基　　金：广东省惠州市科技计划项目(2019Y174)。

摘　　要：目的分析雄激素受体在预测人表皮生长因子受体2(HER-2)过表达型及三阴性乳腺癌化疗敏感性中的价值。方法选取2018年1月至2020年12月广东省惠州市第三人民医院乳腺中心收治的120例乳腺癌患者作为研究对象,按照雄激素受体表达情况将患者分为雄激素受体阳性组、雄激素受体阴性组,且对其病理特征进行分析,如月经情况、肿物大小、Ki-67指数、淋巴结状态、病理类型、病理分期、有无神经侵犯及脉管癌栓、组织学分级,分析雄激素受体表达情况与HER-2过表达型及三阴性乳腺癌患者新辅助化疗敏感性的关系。结果120例患者中47例患者为雄激素受体阳性,73例患者为雄激素受体阴性;雄激素受体阳性组的Ki-67指数<20%、组织学分级为3级、病理分期为Ⅲ期的人数多于雄激素受体阴性组,差异有统计学意义(P<0.05);而两组的年龄、淋巴结转移状态、肿物大小、病理类型、月经情况、有神经侵犯及脉管癌栓比较,差异无统计学意义(P>0.05)。在采用新辅助化疗的60例患者中,试验组的pCR率低于对照组,差异有统计学意义(P<0.05)。结论雄激素受体表达能对三阴性乳腺癌和HER-2过表达型乳腺癌新辅助治疗的疗效进行预测。Objective To analyze the value of androgen receptor in predicting the overexpression of human epidermal growth factor receptor 2(HER-2)and the chemosensitivity of triple negative breast cancer.Methods A total of 120 patients with breast cancer treated in the breast center of the Third People's Hospital of Huizhou City from January 2018 to December 2020 were selected as the research objects.According to the expression of androgen receptor,the patients were divided into androgen receptor positive group and androgen receptor negative group,and their pathological characteristics were analyzed,such as menstruation,tumor size,Ki-67 index,lymph node status,pathological type,pathological stage,whether there was nerve invasion,vascular tumor thrombus The relationship between androgen receptor expression and HER-2 overexpression and neoadjuvant chemotherapy sensitivity in patients with triple negative breast cancer was analyzed.Results Among the 120 patients,47 patients were androgen receptor positive,and 73 patients were androgen receptor negative;the Ki-67 index in the androgen receptor positive group was less than 20%,histological grade was grade 3,and histological stage wasⅢ.The number of patients in the two groups was more than that of the androgen receptor negative group,and the difference was statistically significant(P<0.05).There were no significant differences in age,lymph node metastasis status,tumor size,pathological type,menstrual status nerve invasion and vascular cancer thrombus between the two groups(P>0.05).Among the 60 patients receiving neoadjuvant chemotherapy,the pCR rate of the test group was lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Androgen receptor expression can predict the efficacy of neoadjuvant therapy for triple negative breast cancer and HER-2 overexpression type breast cancer.

关 键 词：雄激素受体 三阴性 人表皮生长因子受体2过表达 乳腺癌 化疗 

分 类 号：R737.9[医药卫生—肿瘤]